Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer

H. Song; T. Koessler; S. Ahmed; S.J. Ramus; S.K. Kjaer; R.A. DiCioccio; E. Wozniak; A.S. Whittemore; V. McGuire; B.A. Ponder; C. Turnbull; S. Hines; N. Rahman; R.A. Eeles; D.F. Easton; S.A. Gayther; A.M. Dunning; P.D. Pharoah; Estrid Vilma Solyom Høgdall

Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer

H. Song, T. Koessler, S. Ahmed, S.J. Ramus, S.K. Kjaer, R.A. DiCioccio, E. Wozniak, A.S. Whittemore, V. McGuire, B.A. Ponder, C. Turnbull, S. Hines, N. Rahman, R.A. Eeles, D.F. Easton, S.A. Gayther, A.M. Dunning, P.D. Pharoah, Estrid Vilma Solyom Høgdall

9 Citationer (Scopus)

Abstract

Several prostate cancer susceptibility loci have recently been identified by genome-wide association studies. These loci are candidates for susceptibility to other epithelial cancers. The aim of this study was to test these tag single nucleotide polymorphisms (SNP) for association with invasive ovarian, colorectal, and breast cancer. Twelve prostate cancer-associated tag SNPs were genotyped in ovarian (2,087 cases/3,491 controls), colorectal (2,148 cases/2,265 controls) and breast (first set, 4,339 cases/4,552 controls; second set, 3,800 cases/3,995 controls) case-control studies. The primary test of association was a comparison of genotype frequencies between cases and controls, and a test for trend stratified by study where appropriate. Genotype-specific odds ratios (OR) were estimated by logistic regression. SNP rs2660753 (chromosome 3p12) showed evidence of association with ovarian cancer [per minor allele OR, 1.19; 95% confidence interval (95% CI), 1.04-1.37; P(trend) = 0.012]. This association was stronger for the serous histologic subtype (OR, 1.29; 95% CI, 1.09-1.53; P = 0.003). SNP rs7931342 (chromosome 11q13) showed some evidence of association with breast cancer (per minor allele OR, 0.95; 95% CI, 0.91-0.99; P(trend) = 0.028). This association was somewhat stronger for estrogen receptor-positive tumors (OR, 0.92; 95% CI, 0.87-0.98; P = 0.011). None of these tag SNPs were associated with risk of colorectal cancer. In conclusion, loci associated with risk of prostate cancer may also be associated with ovarian and breast cancer susceptibility. However, the effects are modest and warrant replication in larger studies
Udgivelsesdato: 2008/11/1

Originalsprog	Dansk
Tidsskrift	Cancer Research
Vol/bind	68
Udgave nummer	21
Sider (fra-til)	8837-8842
Antal sider	5
ISSN	0008-5472
Status	Udgivet - 2008

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Citationsformater

Song, H., Koessler, T., Ahmed, S., Ramus, S. J., Kjaer, S. K., DiCioccio, R. A., Wozniak, E., Whittemore, A. S., McGuire, V., Ponder, B. A., Turnbull, C., Hines, S., Rahman, N., Eeles, R. A., Easton, D. F., Gayther, S. A., Dunning, A. M., Pharoah, P. D., & Høgdall, E. V. S. (2008). Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer. Cancer Research, 68(21), 8837-8842.

Song, H, Koessler, T, Ahmed, S, Ramus, SJ, Kjaer, SK, DiCioccio, RA, Wozniak, E, Whittemore, AS, McGuire, V, Ponder, BA, Turnbull, C, Hines, S, Rahman, N, Eeles, RA, Easton, DF, Gayther, SA, Dunning, AM, Pharoah, PD & Høgdall, EVS 2008, 'Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer', Cancer Research, bind 68, nr. 21, s. 8837-8842.

@article{ead757b08d6811de8bc9000ea68e967b,

title = "Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer",

abstract = "Several prostate cancer susceptibility loci have recently been identified by genome-wide association studies. These loci are candidates for susceptibility to other epithelial cancers. The aim of this study was to test these tag single nucleotide polymorphisms (SNP) for association with invasive ovarian, colorectal, and breast cancer. Twelve prostate cancer-associated tag SNPs were genotyped in ovarian (2,087 cases/3,491 controls), colorectal (2,148 cases/2,265 controls) and breast (first set, 4,339 cases/4,552 controls; second set, 3,800 cases/3,995 controls) case-control studies. The primary test of association was a comparison of genotype frequencies between cases and controls, and a test for trend stratified by study where appropriate. Genotype-specific odds ratios (OR) were estimated by logistic regression. SNP rs2660753 (chromosome 3p12) showed evidence of association with ovarian cancer [per minor allele OR, 1.19; 95% confidence interval (95% CI), 1.04-1.37; P(trend) = 0.012]. This association was stronger for the serous histologic subtype (OR, 1.29; 95% CI, 1.09-1.53; P = 0.003). SNP rs7931342 (chromosome 11q13) showed some evidence of association with breast cancer (per minor allele OR, 0.95; 95% CI, 0.91-0.99; P(trend) = 0.028). This association was somewhat stronger for estrogen receptor-positive tumors (OR, 0.92; 95% CI, 0.87-0.98; P = 0.011). None of these tag SNPs were associated with risk of colorectal cancer. In conclusion, loci associated with risk of prostate cancer may also be associated with ovarian and breast cancer susceptibility. However, the effects are modest and warrant replication in larger studies Udgivelsesdato: 2008/11/1",

author = "H. Song and T. Koessler and S. Ahmed and S.J. Ramus and S.K. Kjaer and R.A. DiCioccio and E. Wozniak and A.S. Whittemore and V. McGuire and B.A. Ponder and C. Turnbull and S. Hines and N. Rahman and R.A. Eeles and D.F. Easton and S.A. Gayther and A.M. Dunning and P.D. Pharoah and H{\o}gdall, {Estrid Vilma Solyom}",

note = "IS - 1538-7445 (Electronic)LA - engPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tSB - IM",

year = "2008",

language = "Dansk",

volume = "68",

pages = "8837--8842",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research",

number = "21",

}

TY - JOUR

T1 - Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer

AU - Song, H.

AU - Koessler, T.

AU - Ahmed, S.

AU - Ramus, S.J.

AU - Kjaer, S.K.

AU - DiCioccio, R.A.

AU - Wozniak, E.

AU - Whittemore, A.S.

AU - McGuire, V.

AU - Ponder, B.A.

AU - Turnbull, C.

AU - Hines, S.

AU - Rahman, N.

AU - Eeles, R.A.

AU - Easton, D.F.

AU - Gayther, S.A.

AU - Dunning, A.M.

AU - Pharoah, P.D.

AU - Høgdall, Estrid Vilma Solyom

N1 - IS - 1538-7445 (Electronic)LA - engPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tSB - IM

PY - 2008

Y1 - 2008

N2 - Several prostate cancer susceptibility loci have recently been identified by genome-wide association studies. These loci are candidates for susceptibility to other epithelial cancers. The aim of this study was to test these tag single nucleotide polymorphisms (SNP) for association with invasive ovarian, colorectal, and breast cancer. Twelve prostate cancer-associated tag SNPs were genotyped in ovarian (2,087 cases/3,491 controls), colorectal (2,148 cases/2,265 controls) and breast (first set, 4,339 cases/4,552 controls; second set, 3,800 cases/3,995 controls) case-control studies. The primary test of association was a comparison of genotype frequencies between cases and controls, and a test for trend stratified by study where appropriate. Genotype-specific odds ratios (OR) were estimated by logistic regression. SNP rs2660753 (chromosome 3p12) showed evidence of association with ovarian cancer [per minor allele OR, 1.19; 95% confidence interval (95% CI), 1.04-1.37; P(trend) = 0.012]. This association was stronger for the serous histologic subtype (OR, 1.29; 95% CI, 1.09-1.53; P = 0.003). SNP rs7931342 (chromosome 11q13) showed some evidence of association with breast cancer (per minor allele OR, 0.95; 95% CI, 0.91-0.99; P(trend) = 0.028). This association was somewhat stronger for estrogen receptor-positive tumors (OR, 0.92; 95% CI, 0.87-0.98; P = 0.011). None of these tag SNPs were associated with risk of colorectal cancer. In conclusion, loci associated with risk of prostate cancer may also be associated with ovarian and breast cancer susceptibility. However, the effects are modest and warrant replication in larger studies Udgivelsesdato: 2008/11/1

AB - Several prostate cancer susceptibility loci have recently been identified by genome-wide association studies. These loci are candidates for susceptibility to other epithelial cancers. The aim of this study was to test these tag single nucleotide polymorphisms (SNP) for association with invasive ovarian, colorectal, and breast cancer. Twelve prostate cancer-associated tag SNPs were genotyped in ovarian (2,087 cases/3,491 controls), colorectal (2,148 cases/2,265 controls) and breast (first set, 4,339 cases/4,552 controls; second set, 3,800 cases/3,995 controls) case-control studies. The primary test of association was a comparison of genotype frequencies between cases and controls, and a test for trend stratified by study where appropriate. Genotype-specific odds ratios (OR) were estimated by logistic regression. SNP rs2660753 (chromosome 3p12) showed evidence of association with ovarian cancer [per minor allele OR, 1.19; 95% confidence interval (95% CI), 1.04-1.37; P(trend) = 0.012]. This association was stronger for the serous histologic subtype (OR, 1.29; 95% CI, 1.09-1.53; P = 0.003). SNP rs7931342 (chromosome 11q13) showed some evidence of association with breast cancer (per minor allele OR, 0.95; 95% CI, 0.91-0.99; P(trend) = 0.028). This association was somewhat stronger for estrogen receptor-positive tumors (OR, 0.92; 95% CI, 0.87-0.98; P = 0.011). None of these tag SNPs were associated with risk of colorectal cancer. In conclusion, loci associated with risk of prostate cancer may also be associated with ovarian and breast cancer susceptibility. However, the effects are modest and warrant replication in larger studies Udgivelsesdato: 2008/11/1

M3 - Tidsskriftartikel

SN - 0008-5472

VL - 68

SP - 8837

EP - 8842

JO - Cancer Research

JF - Cancer Research

IS - 21

ER -